A5033432886- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Platelet Disorders and Treatments
- Blood groups and transfusion
- Systemic Lupus Erythematosus Research
- Immunotherapy and Immune Responses
- Blood properties and coagulation
- Urinary and Genital Oncology Studies
- Systemic Sclerosis and Related Diseases
Hospital Del Mar
2023-2025
Municipal Institute for Medical Research
2023
Institut de recherche mathématique de Rennes
2023
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and can result in complete remissions even at advanced stages of the disease. However, only a small fraction patients respond to treatment. To better understand which factors drive clinical benefit, we generated whole exome RNA sequencing data from 27 urothelial carcinoma treated with anti-PD-(L)1 monoclonal antibodies. We assessed influence on response non-synonymous mutations (tumor mutational burden or TMB), clonal...
ABSTRACT Advanced bladder cancer patients show very variable responses to immune checkpoint inhibitors (ICIs) and effective strategies predict response are still lacking. Here we integrate mutation gene expression data from 707 advanced treated with anti-PD-1/anti-PD-L1 build highly accurate predictive models. We find that, in addition tumor mutational burden (TMB), enrichment the APOBEC signature, abundance of pro-inflammatory macrophages, major factors associated response. Paradoxically,...
ABSTRACT Muscle-invasive bladder cancer (MIBC) is associated with poor predictability of response to cisplatin-based neoadjuvant chemotherapy (NAC). Consequently, the benefit NAC remains unclear for many patients due lack reliable biomarkers. In order identify biomarkers and build an integrated accurate model predict response, we conducted a comprehensive transcriptomic genomic profiling on 100 MIBC patient tumors. Our analysis identified 602 differentially expressed genes between responders...
Topic: 32. Platelet disorders Background: Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide range of manifestations, including immune thrombocytopenia (ITP). The presence ITP has been described in 7-40% SLE patients. Aims: To create predictive model to identify those patients at risk developing over the course cohort Hospital del Mar. Methods: We conducted retrospective case-control study which 407 medical records were reviewed: 22 had developed after diagnosis (cases)...
Abstract Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and can result in complete remissions even at advanced stages of the disease. However, only a small fraction patients respond to treatment. To better understand which factors drive clinical benefit, we generated whole exome RNA sequencing data from 27 urothelial carcinoma treated with anti-PD-(L)1 monoclonal antibodies. We assessed influence on response non-synonymous mutations (tumor mutational burden or TMB),...